A selection of major announcements
1. Tencent's Q4 revenue was 155.196 billion yuan, up 7% year-on-year
$TENCENT (00700.HK)$Results for the fourth quarter ended December 31, 2023 were announced. Q4 revenue was 155.196 billion yuan, up 7% year on year; net profit was 27.025 billion yuan, down 75% year on year; adjusted net profit was 42,681 billion yuan, up 44% year on year.
Tencent Holdings proposes to pay a dividend of HK$3.40 per share (approximately HK$32 billion) for the year ended 31 December 2023, an increase of 42%, and plans to at least double the share repurchase scale from HK$49 billion in 2023 to over HK$100 billion in 2024.
2. Kuaishou's Q4 revenue was 32,561 billion yuan, an increase of 15.1% over the previous year
$KUAISHOU-W (01024.HK)$Revenue for 2023Q4 was RMB 32.561 billion, up 15.1% year on year; adjusted net profit was RMB 4.362 billion, compared with a loss of RMB 45 million for the same period of the previous year.
3. Jinshan Software: Achieving net profit of 484 million yuan in 2023, with a proposed final interest of HK$0.14 per share
$KINGSOFT (03888.HK)$According to the announcement, revenue for 2023 was RMB 8,533.6 billion, an increase of 12% over the same period last year. Profit attributable to parent company owners in 2023 was RMB483.5 million, compared to a loss of RMB6.049.4 billion for the previous year. The Board recommended a final dividend of HK$0.14 per share.
4. China Coal Energy: Profit attributable to shareholders increased by 2.3% to RMB 20.084 billion in 2023, with a final interest of RMB 0.442
$CHINA COAL (01898.HK)$Announcing the results for the year ended December 31, 2023, the Group obtained revenue of RMB 192,969 billion (same unit), a year-on-year decrease of 12.52%; profit attributable to the company's shareholders of RMB 20.84 billion, an increase of 2.26% over the previous year; profit per share of 1.52 yuan, and a final dividend of RMB 0.442 per share.
Earnings Report
$TENCENT (00700.HK)$Q4 revenue was 155.196 billion yuan, up 7% year-on-year
$KUAISHOU-W (01024.HK)$Q4 revenue was RMB 32.561 billion, up 15.1% year over year
$CHINA COAL (01898.HK)$Profit attributable to shareholders increased by 2.3% to RMB 20.084 billion in final interest of RMB 0.442
$BANK OF TIANJIN (01578.HK)$Profit before provision in 2023 increased by 3.1% to 11.69 billion yuan, 1.2 yuan for every 10 shares
$CKI HOLDINGS (01038.HK)$: Achieve net profit of HK$8 billion in 2023, and plan to distribute final interest of HK$1.85 per share
$HK & CHINA GAS (00003.HK)$Profit after tax attributable to shareholders of HK$6.07 billion rose 16% year over year in 2023
$POWER ASSETS (00006.HK)$: Achieve net profit of HK$6.03 billion in 2023, and plan to distribute final interest of HK$2.4 per share
$HWORLD-S (01179.HK)$Net profit of RMB 4.1 billion in 2023 is expected to increase revenue by 8% to 12% in 2024
$SUNNY OPTICAL (02382.HK)$Profit attributable to shareholders decreased by approximately 54.3% to approximately HK$1.1 billion with final interest of HK$0.219
$SIMCERE PHARMA (02096.HK)$Revenue of about 6.608 billion yuan in 2023 increased by about 4.5% year-on-year
$KINGSOFT (03888.HK)$: Achieve net profit of $484 million to mother in 2023, and plan to distribute final interest of HK$0.14 per share
$SISRAM MED (01696.HK)$Annual profit decreased by 17.9% to $32.9 million
$SOLOMON SYSTECH (02878.HK)$Net profit of $19.4 million in 2023 fell 30.1% year over year
Operational data
$CHINA MOBILE (00941.HK)$: In February, the total number of 5G package customers reached 8008 million
$CHINA TELECOM (00728.HK)$February operating data released: 5G package users reached 324 million
$CHINA RES POWER (00836.HK)$: Electricity sales of affiliated power plants increased by 7.4% in the first two months, sales volume of photovoltaic power plants increased by 201.9%
Pharmaceutical Innovation
$FOSUN PHARMA (02196.HK)$: The holding subsidiary passed the GMP compliance inspection
$CANSINOBIO (06185.HK)$: Adsorbed tetanus vaccine begins phase III clinical trial and completes first patient enrollment
$CSPC PHARMA (01093.HK)$: Antibody drug conjugate SYS6023 approved for clinical trials
Repurchase cancellation
$SIMCERE PHARMA (02096.HK)$Revise the maximum total price under the existing share repurchase proposal from $500 million to $1 billion
$AIA (01299.HK)$5.45 million shares were repurchased at HK$307 million on March 20
$HSBC HOLDINGS (00005.HK)$On March 19, it spent HK$124 million to repurchase 2.104,400 shares
$BEKE-W (02423.HK)$On March 19, it cost 15 million US dollars to buy back 3.147 million shares
$WUXI APPTEC (02359.HK)$On March 20, it spent 2010 million yuan to buy back 398,700 A-shares
$SWIRE PACIFIC A (00019.HK)$On March 20, 156,500 shares were purchased at HK$9.99 million
$STANCHART (02888.HK)$On March 19, it cost £7.919,500 to buy back 1.21 million shares
$YUM CHINA (09987.HK)$14,500 shares were purchased at HK$4.65 million on March 19
$SINOPEC SEG (02386.HK)$On March 20, 645,000 shares were repurchased at HK$2,923 million
Editor/Somer